SciSparc to Conduct a Phase IIa Clinical Trial in Alzheimer's Patients Using the Company's Proprietary Cannabinoid-Based Treatment
Retrieved on:
Wednesday, February 17, 2021
Alzheimer's disease is the most common type of dementia, accounting for over two-thirds of cases of dementia.
Key Points:
- Alzheimer's disease is the most common type of dementia, accounting for over two-thirds of cases of dementia.
- Alzheimer's disease is a neurodegenerative disease that causes progressive and disabling impairment of cognitive functions including memory, comprehension, language, attention, reasoning and judgment.
- The current pharmacological treatment of agitation in Alzheimer's disease has an unsatisfactory benefit/risk ratio and often involves using off-label drugs.
- The Alzheimer's center treats hundreds of patients a year, as inpatients, outpatients and as part of its diagnosis and counseling services.